CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 80 enrolled
Drug / intervention
Quatera 700 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06225362
NCT06225362N/ACompleted

Evaluation and Clinical Outcomes After Routine Cataract Surgery With the Quatera® 700 and the Centurion® Vision System

Carolina Eyecare Physicians, LLC·interventional·Posted Jan 25, 2024·Updated Apr 1, 2026

In Brief

A clinical study evaluating Quatera 700 and Centurion for Cataract. Completed, enrolled 80 participants across 1 site.

Detailed Summary

Phacoemulsification is the most common treatment for cataract surgery in the developed countries and over the years it gained importance due to several factors: small incision, surgery performed under topical anesthesia - which reduce injection-related complications - short recovery time, low post operatory induced astigmatism, and low incidence of surgical complications, when compared to the conventional surgeries. The study evaluates 2 different phacoemulsification devices in patients undergoing routine cataract surgery in both eyes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
CollaboratorsScience in Vision

Timeline

N/ACompletedFinished
202420252026
First PostedJan 25, 2024
Enrollment StartJan 10, 2024
Primary CompletionOct 6, 2025
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 2.4 years ago

Interventions

Quatera 700device

Phacoemulsification device

Centuriondevice

Phacoemulsification device